Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players Earlier on Friday, Novo Nordisk A/S (NYSE:NVO) announced headline results from a phase 2a clinical trial with monlunabant, a small-mo...